{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:04:10Z","timestamp":1775235850985,"version":"3.50.1"},"reference-count":47,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,15]]},"DOI":"10.2169\/internalmedicine.4646-20","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T22:06:03Z","timestamp":1594073163000},"page":"2611-2618","source":"Crossref","is-referenced-by-count":15,"title":["Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-\u03b1 and IL-6 Therapy in a Patient with Rheumatoid Arthritis"],"prefix":"10.2169","volume":"59","author":[{"given":"Noritada","family":"Yoshikawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Rheumatology, Center for Antibody and Vaccine Therap, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohisa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Rheumatology, Center for Antibody and Vaccine Therap, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Teikyo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Rheumatology, Center for Antibody and Vaccine Therap, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford) 57: 1896-1907, 2018."},{"key":"2","unstructured":"2. Winthrop KL, Weinblatt ME, Crow MK, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis 78: 872-878, 2019."},{"key":"3","unstructured":"3. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 30: 490-497, 2018."},{"key":"4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"4. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 381: 320-332, 2013.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol 32: 364-375, 2014.","DOI":"10.1016\/j.clindermatol.2013.11.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ljubojevic S, Lipozen\u010di\u0107 J. Autoimmune bullous diseases associations. Clin Dermatol 30: 17-33, 2012.","DOI":"10.1016\/j.clindermatol.2011.03.006"},{"key":"7","unstructured":"7. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 28: 1133-1140, 2014."},{"key":"8","unstructured":"8. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sj\u00f6gren's syndrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol 46: 1102-1135, 2019.","DOI":"10.1111\/1346-8138.15111"},{"key":"10","unstructured":"10. Petri M, Orbai AM, Alarc\u00f3n GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-2686, 2012."},{"key":"11","unstructured":"11. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71: 1400-1412, 2019."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chua-Aguilera CJ, M\u00f6ller B, Yawalkar N. Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53: 371-393, 2017.","DOI":"10.1007\/s12016-017-8632-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and mucosal manifestations of Sj\u00f6gren's syndrome. Clin Rev Allergy Immunol 53: 357-370, 2017.","DOI":"10.1007\/s12016-017-8639-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Maggio MC, Corsello G, Prinzi E, Cimaz R. Systemic lupus erythematosus and bullous pemphigoid with dramatic response to dapsone. Am J Case Rep 18: 317-319, 2017.","DOI":"10.12659\/AJCR.902351"},{"key":"15","unstructured":"15. Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol 15: 517-524, 2014."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22: 847-861, 2008.","DOI":"10.1016\/j.berh.2008.09.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hoffmann S, Berneburg M, Schreml S. Bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis. Case Rep Dermatol 10: 145-148, 2018.","DOI":"10.1159\/000489163"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wessman LL, Blixt EK, Wetter DA, Miest RY. Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis. JAAD Case Rep 3: 339-341, 2017.","DOI":"10.1016\/j.jdcr.2017.03.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wilmer EN, Becker N, Chen A, Kroumpouzos G. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep 2: 25-27, 2016.","DOI":"10.1016\/j.jdcr.2015.12.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ricci M, Zauli S, Zelante A, Trevisani L, Virgili A, Bettoli V. Bullous pemphigoid occurring under anti-tumor necrosis factor-\u03b1 therapy. Int J Colorectal Dis 29: 1573-1574, 2014.","DOI":"10.1007\/s00384-014-1924-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mochizuki M, Fujine E, Tawada C, Kanoh H, Seishima M. Pemphigoid nodularis possibly induced by etanercept. J Dermatol 40: 578-579, 2013.","DOI":"10.1111\/1346-8138.12171"},{"key":"22","unstructured":"22. Kluk J, Goulding JM, Bhat J, Finch TM. Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol 36: 871-873, 2011."},{"key":"23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000318008","volume":"221","author":"L Boussemart","year":"2010","unstructured":"23. Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 221: 201-205, 2010.","journal-title":"Dermatology","ISSN":"https:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Altindag O, Aydeniz A, Gursoy S. A case with anti TNF-alpha induced bullous pemhigoid. Turk J Rheumatol 25: 214-216, 2010.","DOI":"10.5152\/tjr.2010.31"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Stausb\u00f8l-Gr\u00f8n B, Deleuran M, Sommer Hansen E, Kragballe K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 34: e285-e286, 2009.","DOI":"10.1111\/j.1365-2230.2008.03204.x"},{"key":"26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000243805","volume":"219","author":"M Bordignon","year":"2009","unstructured":"26. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 219: 357-358, 2009.","journal-title":"Dermatology","ISSN":"https:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"27","unstructured":"27. Gibson FT, Amber KT. Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review. Int J Dermatol 59: 520-524, 2020."},{"key":"28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbspin.2017.01.002","volume":"85","author":"W Terreaux","year":"2018","unstructured":"28. Terreaux W, Masson C, Eschard JP, et al. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. Joint Bone Spine 85: 53-57, 2018.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0961203314523871","volume":"23","author":"S Ara\u00fajo-Fern\u00e1ndez","year":"2014","unstructured":"29. Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus 23: 545-553, 2014.","journal-title":"Lupus","ISSN":"https:\/\/id.crossref.org\/issn\/0961-2033","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129-134, 1998.","DOI":"10.1084\/jem.187.1.129"},{"key":"31","unstructured":"31. Guggino G, Giardina AR, Raimondo S, et al. Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion. Clin Exp Rheumatol 32: 77-81, 2014."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Gounni Abdelilah S, Wellemans V, Agouli M, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol 120: 220-231, 2006.","DOI":"10.1016\/j.clim.2006.03.014"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Thorlacius GE, Wahren-Herlenius M, R\u00f6nnblom L. An update on the role of type I interferons in systemic lupus erythematosus and Sj\u00f6gren's syndrome. Curr Opin Rheumatol 30: 471-481, 2018.","DOI":"10.1097\/BOR.0000000000000524"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102: 3372-3377, 2005.","DOI":"10.1073\/pnas.0408506102"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept. Arthritis Rheum 56: 3995-4004, 2007.","DOI":"10.1002\/art.23062"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 12: R11, 2010.","DOI":"10.1186\/ar2912"},{"key":"37","unstructured":"37. Ishikawa Y, Fujii T, Ishikawa SK, et al. Immunogenicity and lupus-like autoantibody production can be linked to each other along with type I interferon production in patients with rheumatoid arthritis treated with infliximab: a retrospective study of a single center cohort. PLoS One 11: e0162896, 2016."},{"key":"38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000247329","volume":"186","author":"A Parodi","year":"1993","unstructured":"38. Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186: 155-157, 1993.","journal-title":"Dermatology","ISSN":"https:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Henault J, Riggs JM, Karnell JL, et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat Immunol 17: 196-203, 2016.","DOI":"10.1038\/ni.3326"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 144: 41-48, 2008.","DOI":"10.1001\/archdermatol.2007.9"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"42","unstructured":"42. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity 44: 973-988, 2016."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18: 374-384, 2017.","DOI":"10.1038\/ni.3691"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol 11: 616-620, 2015.","DOI":"10.1038\/nrrheum.2015.86"},{"key":"45","unstructured":"45. Samotij D, Reich A. Biologics in the treatment of lupus erythematosus: a critical literature review. Biomed Res Int 2019: 8142368, 2019."},{"key":"46","unstructured":"46. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392: 222-231, 2018."},{"key":"47","unstructured":"47. Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol 15: 693-700, 2019."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4646-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:43:52Z","timestamp":1602906232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4646-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":47,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4646-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}